ALBANY, New York, September 17, 2012-The report provides an overview of the most exciting innovations in drug delivery technologies in major therapeutic areas oncology, vaccines, diabetes, rheumatology and respiratory diseases. Each chapter highlights emerging companies with technologies that have the potential to transform drug delivery in that specific therapeutic area. The report also explores the current environment in healthcare and the pharmaceutical industry, and examines drivers and challenges for the use of innovative drug delivery technologies.
Drug delivery technologies provide commercial opportunities for pharmaceutical companies by improving the chances of success for a drug development project. They enable the formulation of a promising molecule that might have poor solubility or require selective delivery to a particular tissue, such as the brain. Similarly, drug delivery technologies may enable companies to differentiate products within crowded therapeutic areas, facilitate life cycle management for existing drugs, and reposition existing drugs proprietary or generic in new indications where the needs of the patient population are different or, again, where more targeted delivery is required.
Products that are reformulated with novel drug delivery systems do not meet the traditional criteria for innovative products in other words, products that include new active moieties. Nevertheless, GBI Researchs analysis shows that the commercial success of existing products that rely on innovative drug delivery technologies is clear, and these products make significant positive changes for patients.
PR Newswire